重要内容提示： 利润分配总额调整：威海百合生物技术股份有限公司（以下简称"公司"） 2024 年利润分配总额由人民币 47,165,400 元（含税）调整至人民币 46,705,425 元（含税）。 本次调整的原因：实施权益分派股权登记日前，公司完成以集中竞价交 易方式股份回购方案，导致公司实际参与利润分配的股份总数发生变化，公司拟 维持每股分配比例不变，相应调整分配总额。 证券代码：603102 证券简称：百合股份 公告编号：2025-028 威海百合生物技术股份有限公司 关于调整 2024 年度利润分配总额的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 依据上述回购专用证券账户股数变动情况及公司 2024 年年度股东大会审议 通过的《关于 2024 年度利润分配预案的议案》，公司拟维持每股分配金额不变， 以权益分派的股权登记日登记的总股本扣除公司回购专户中的股份数后为基数， 相应调整现金分配总额。调整后的公司 2024 年度利润分配方案如下： 公司拟向全体股东每 10 股派发现金红利 7.50 元（含税），不进行资 ...

Summary of Key Points Core Viewpoint - The announcement details the completion of a share reduction plan by the company's director, Wang Wentong, who has reduced his holdings in the company. Group 1: Shareholding Information - Before the reduction plan, director Wang Wentong held 1,697,518 shares, accounting for 2.65% of the company's total share capital [1] - The shares held by Wang Wentong were all acquired prior to the company's initial public offering [1] Group 2: Reduction Plan Implementation - The reduction plan was first disclosed on May 22, 2025, with the reduction period set from June 13 to July 16, 2025 [2] - Wang Wentong has reduced his holdings by 424,000 shares, which is 0.6625% of the company's total share capital, through centralized bidding [2] - The total amount from the reduction was 19,145,390 yuan, with the share price ranging from 44.42 to 45.55 yuan per share [2] - After the reduction, Wang Wentong holds 1,273,518 shares, representing 1.99% of the company's total share capital [2]

证券代码：603102 证券简称：百合股份 公告编号：2025-027 威海百合生物技术股份有限公司 董事减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次减持计划实施前，董事王文通先生持有公司股份 1,697,518 股，占公司 总股本的 2.65%，上述股份全部来源于公司首次公开发行股票前已持有的股份。 (一)大股东及董监高因以下事项披露减持计划实施结果： 董事持股的基本情况 减持计划的实施结果情况 公司于 2025 年 5 月 22 日披露了《威海百合生物技术股份有限公司董事减持 股份计划公告》（公告编号：2025-020），董事王文通计划于 2025 年 6 月 13 日至 2025 年 9 月 12 日期间通过集中竞价减持公司股份不超过 424,000 股，不超过公 司总股本的 0.6625%，具体内容详见公告。截至本公告披露之日，董事王文通， 通过集中竞价方式累计减持公司股份 424,000 股，占公司总股本的 0.6625%，董 事王文通先生本次减持计划实施完毕。 1 ...

百合股份（603102）公告，公司董事王文通于2025年6月13日至2025年7月16日期间通过集中竞价方式累 计减持公司股份42.4万股，占公司总股本的0.6625%，减持价格区间为44.42～45.55元/股，减持总金额 为1914.54万元。本次减持计划实施完毕后，王文通先生当前持股数量为127.35万股，持股比例降至 1.99%。本次实际减持情况与此前披露的减持计划一致。 ...

证券代码：603102 证券简称：百合股份 公告编号：2025-026 威海百合生物技术股份有限公司 关于股份回购比例达 1%、股份回购实施结果 暨股份变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/8/9，由董事长提议 | | | | | | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 年 月 月 2024 8 8 | 8 | 日~2025 | 年 | 日 7 | | 预计回购金额 | 3,000万元~6,000万元 | | | | | | 回购价格上限 | 50.00元/股 | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | | | | | □用于转换公司可转债 | | | | | | | □为维护公司价值及股东权益 | | | | | | 实际回购股数 | 70.57万股 | | | | | | 实际回购股数占总股本比例 | 1.10% | | | | | | ...

Core Points - The company has adjusted the maximum repurchase price from RMB 42 per share to RMB 50 per share, which is not more than 150% of the average stock price over the last 30 trading days prior to the decision [1][2] - Other aspects of the repurchase plan remain unchanged, and the adjustment does not require shareholder approval [1][3] Repurchase Plan Overview - The company approved a share repurchase plan on August 8, 2024, with a total repurchase amount between RMB 30 million and RMB 60 million, and a repurchase period of 12 months [1][2] - As of now, the company has repurchased 248,500 shares, accounting for 0.39% of the total share capital, with a total expenditure of approximately RMB 9.78 million [2] Impact of Price Adjustment - The adjustment of the repurchase price is intended to facilitate the smooth implementation of the repurchase plan and to protect the company's value and shareholder interests [2][3] - The estimated additional repurchase quantity ranges from 652,900 to 1,252,900 shares, representing approximately 1.02% to 1.96% of the total share capital [3] Decision-Making Process - The adjustment was approved by the company's fourth board of directors' twelfth meeting and does not require further shareholder approval [3]

证券代码：603102 证券简称：百合股份 公告编号：2025-025 威海百合生物技术股份有限公司 关于调整回购股份价格上限的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次回购股份价格上限由人民币 42 元/股（含）调整至人民币 50 元/股 （含），该价格不高于董事会审议通过本次调整回购股份价格决议前 30 个交易 日公司股票均价的 150%。 一、回购股份的基本情况 公司于 2024 年 8 月 8 日召开第四届董事会第九次会议，审议通过了《关于 以集中竞价交易方式回购公司股份方案的议案》，同意公司以自有或自筹资金以 集中竞价交易方式回购部分公司股份，本次回购股份将在未来适宜时机全部用于 员工持股计划或股权激励，回购价格不超过人民币 42 元/股（含），回购资金总 额不低于人民币 3,000 万元（含），不超过人民币 6,000 万元（含），回购期限 为自董事会审议通过本次回购方案之日起 12 个月内，具体内容详见公司在上海 证券交易所网站（www.sse.com.cn）披露的《关于以集中竞价 ...

Core Viewpoint - The dispute between Weihai Baihe Biotechnology Co., Ltd. (Baihe) and Shandong Hailaiyunshi Co., Ltd. (Hailaiyunshi) has raised concerns over potential commercial bribery, impacting Baihe's market image and future prospects [1][2][3] Group 1: Dispute Background - The conflict originated from a discarded contract signed in December 2020 for the production of oat bran and other meal replacement products [1] - Baihe completed production tasks as per orders in January and March 2021, but Hailaiyunshi ceased issuing new production instructions by the end of March 2021 [1] - In 2024, Baihe claimed that a batch of raw materials prepared for the contract had expired and demanded compensation from Hailaiyunshi, leading to a lawsuit after failed negotiations [1] Group 2: Evidence of Bribery - During the lawsuit, Hailaiyunshi's lawyer discovered a record of a payment of 0.6 yuan per box to Baihe's procurement personnel, potentially amounting to 360,000 yuan based on an annual purchase volume of 600,000 boxes [2] - Key personnel at Baihe, including the vice president and auditors, approved this arrangement, raising suspicions of commercial bribery [2][3] Group 3: Company Performance and Responsibilities - Baihe, known as the "first stock of nutritional health food OEM," reported a revenue of 801 million yuan in 2024, with 84% of this revenue coming from its OEM business [5] - The company faced a revenue decline of 8.02% year-on-year and a net profit drop of 17.60% in 2024, attributed to global economic fluctuations and domestic market adjustments [5] - Baihe is obligated to disclose information regarding the incident, internal investigations, and corrective measures to the market and investors [5]

Core Insights - The article discusses recent developments in the nutrition and health industry, highlighting regulatory changes, new product approvals, and market trends that could impact investment opportunities [2][3][4][5][6]. Regulatory Developments - The State Administration for Market Regulation issued a guideline clarifying the definition of commercial advertising under the Advertising Law, addressing ongoing disputes in advertising enforcement [2]. - The National Health Commission approved D-alloheptulose and four other substances as new food raw materials, indicating a push for innovation in the nutrition sector [3]. - The market regulator released multiple responses to proposals regarding health food regulations, signaling a focus on traditional Chinese medicine formulations as a potential growth area [4]. Market Trends and Investment Opportunities - Yangtuo Technology Inc. submitted an IPO application to the Hong Kong Stock Exchange, aiming to raise funds for market expansion and supply chain optimization, reflecting growing investor interest in the nutrition and health sector [5]. - A report on 68 nutrition and health companies showed an average market value increase of 20% in the first half of the year, driven by rising consumer health awareness and demand for nutritional products [6]. Company Performance - New Hope Liuhe (002001) projected a net profit of 3.3 billion to 3.75 billion yuan for the first half of 2025, representing a year-on-year growth of 50% to 70% [12]. - Brother Technology (002562) expects a net profit of 60 million to 75 million yuan for the same period, marking an increase of 325% to 431% compared to the previous year [13]. New Product Launches - Guangji Pharmaceutical (000952) received a notice of administrative penalty for information disclosure violations, indicating regulatory scrutiny in the sector [14]. - TCM brand Tongrentang launched its first OTC glucosamine product, expanding its product line in the bone and joint health category [14].

Group 1 - The health supplement market in China is expected to expand significantly, driven by new demographics and demands, with the vitamin and dietary supplement (VDS) market projected to reach 232.3 billion yuan in 2024, a year-on-year increase of 4% [2] - The market is characterized by high gross margins and marketing expenses, similar to the beauty industry, and is currently undergoing a transformative phase with lower concentration among leading brands [2][3] - New channels and consumer demands are anticipated to drive functionalization in the health supplement industry, creating opportunities for product innovation, particularly through content e-commerce platforms like Douyin [3] Group 2 - Specific categories within the health supplement market are experiencing rapid growth, including fish oil (market size 5-10 billion yuan), coenzyme Q10 (market size 4.1 billion yuan, year-on-year increase of 17%), probiotics (market size over 10 billion yuan), and oral beauty products (market size over 10 billion yuan) [4] - The basic nutrients segment, including vitamins, minerals, and proteins, has a market size of 32.9 billion, 27.1 billion, and 11.6 billion yuan respectively, with year-on-year growth rates of 3%, 5%, and 1%, but faces high product homogeneity [4]